Skip to main content

Patient Recruitment Home

Current Protocols

Ethics in Clinical Research

Privacy Notice

FAQ About Clinical Studies

Contact Us

Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.

For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).

Se habla español.

Patient Recruitment

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine and HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) Clinical Trial

Abstract illustration of cells and the human body

graphic illustration of cells being blocked by a health sheild

Abstract medical illustration of cells

Researchers at the National Institutes of Health (NIH) are conducting an investigational treatment study with the HEPLISAV-B (hepatitis-B) vaccine and/or the SHINGRIX (shingles) vaccine. Eligible volunteers must have either never received treatment for their chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) OR currently be receiving ibrutinib or acalabrutinib for their CLL/SLL. Volunteers will participate in the study for 6 months.

You may be eligible for the SHINGRIX (shingles) vaccine (study # 19-H-0001) if you:

  • Have a diagnosis of CLL or SLL and meet one of the following criteria
  • Have never received treatment for CLL or SLL
  • Are currently receiving ibrutinib or acalabrutinib for at least 6 months
  • Are at least 18 years old
  • Are not receiving IVIG (intravenous immunoglobulin)
  • Are not receiving other immunosuppressing agents (e.g. steroids, rituximab)
  • Have never received the SHINGRIX vaccine before (SHINGRIX vaccine study only)
  • Have not had shingles in the past 12 months
  • Have not received the ZOSTAVAX (live shingles) vaccine in the past 12 months

You may be eligible for the HEPLISAV-B (hepatitis B) vaccine (study# 18-H-0145) if you:

  • Have a diagnosis of CLL or SLL and meet one of the following criteria
  • Have never received treatment for CLL or SLL
  • Are currently receiving ibrutinib or acalabrutinib for at least 6 months
  • Are at least 18 years old
  • Are not receiving IVIG (intravenous immunoglobulin)
  • Are not receiving other immunosuppressing agents (e.g. steroids, rituximab)
  • Have no known active or past hepatitis B infection
  • Have no history of prior hepatitis B virus vaccination (approved or investigational)

To learn how to participate, contact:
Office of Patient Recruitment
1-800-411-1222
(TTY users call via MD Relay 7-1-1)
Se habla español
Email: cc-prpl@cc.nih.gov

Or go online:
https://go.usa.gov/xmyRy (study # 19-H-0001)
https://go.usa.gov/xmyRE (study # 18-H- 0145)

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung and Blood Institute (NHLBI)

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 02/25/2020

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at http://www.cc.nih.gov/disclaimers.html